Immunopotentiative composition

Patent metadata

Field	Value
Publication number	US-9402899-B2
Application number	US-201414245692-A
Country	US
Kind code	B2
Filing date	Apr 4, 2014
Priority date	Jul 3, 2002
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

First claim

The invention claimed is:

1. A method of treating a tumor in a human patient in need thereof comprising
administering to the human an effective amount of an anti-PD-L1 monoclonal antibody that inhibits an interaction between PD-1 and PD-L1,
wherein the anti-PD-L1 monoclonal antibody treats the tumor in the patient.

2. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody is a chimeric, humanized, or human antibody.

3. The method of claim 1 , wherein the tumor is a solid tumor.

4. The method of claim 3 , wherein tumor growth is decreased.

5. The method of claim 1 , wherein tumor metastasis is suppressed.

6. The method of claim 1 , wherein the tumor is one or more selected from a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, a leukemia, a neuroma, a melanoma, and a lymphoma.

7. The method of claim 6 , wherein the squamous carcinoma is in the cervical canal, eyelid, tunica, conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, or gullet.

8. The method of claim 6 , wherein the squamous carcinoma is in the lung.

9. The method of claim 6 , wherein the adenocarcinoma is in the prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, intestinum rectum, uterus, stomach, mammary gland, or ovary.

10. The method of claim 1 , wherein the tumor is melanoma.

11. The method of claim 1 , wherein the patient is further administered an interferon-α.

12. The method of claim 1 , wherein the tumor is in the lung.

13. The method of claim 1 , wherein the patient is farther administered a tumor antigen.

14. The method of claim 13 , wherein the tumor antigen is selected from HLA-A1 or HLA-A2 restrictive peptide of malignant melanoma MAGE-1 or MAGE-3, MART-1, gp100, HER2/neu peptide of a mammary or ovarian carcinoma, MUC-1 peptide of an adenocarcinorna, and NY-ESO-1 of a metastatic carcinoma.

15. The method of claim 1 , wherein the human patient is further administered an an anti-cancer drug.

16. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody is administered systemically.

17. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody is administered orally or parenterally.

18. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody is administered postoperatively.

19. A method of decreasing tumor growth in a human patient in need thereof comprising
administering to the human patient an effective amount of an anti-PD-L1 monoclonal antibody,
wherein the anti-PD-L1 monoclonal antibody inhibits an interaction between PD-1 and PD-L1 and decreases the tumor growth in the human patient.

20. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody is a chimeric, humanized, or human antibody.

21. The method of claim 19 , wherein the tumor is a solid tumor.

22. The method of claim 19 , wherein tumor metastasis is suppressed.

23. The method of claim 19 , wherein the tumor is one or more selected from a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, a leukemia, a neuroma, a melanoma, and a lymphoma.

24. The method of claim 23 , wherein the squamous carcinoma is in the cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, or gullet.

25. The method of claim 23 , wherein the squamous carcinoma is in the lung.

26. The method of claim 23 , wherein the adenocarcinoma is in the prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, intestinum rectum, uterus, stomach, mammary gland, or ovary.

27. The method of claim 19 , wherein the tumor is melanoma.

28. The method of claim 19 , wherein the patient is further administered an interferon-α.

29. The method of claim 19 , wherein the tumor is in the lung.

30. The method of claim 19 , wherein the patient is further administered a tumor antigen.

31. The method of claim 30 , wherein the tumor antigen is selected from HLA-A1 or HLA-A2 restrictive peptide of malignant melanoma MAGE-1 or MAGE-3, MART-1, gp100, HER2/neu peptide of a mammary or ovarian carcinoma, MUC-1 peptide of an adenocarcinoma, and NY-ESO-1 of a metastatic carcinoma.

32. The method of claim 19 , wherein the human patient is further administered an anti-cancer drug.

33. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody is administered systemically.

34. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody is administered orally or parenterally.

35. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody is administered postoperatively.

36. A method of suppressing metastasis tumor cells in a human patient in need thereof comprising administering to the human patient an effective amount of an anti-PD-L1 monoclonal antibody,
wherein the anti-PD-L1 monoclonal antibody inhibits an interaction between PD-1 and PD-L1.

37. The method of claim 36 , wherein the tumor is a solid tumor.

38. The method of claim 36 , wherein the tumor is one or more selected from a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, a leukemia, a neuroma, a melanoma, and a lymphoma.

39. The method of claim 38 , wherein the squamous carcinoma is in the cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, or gullet.

40. The method of claim 38 , wherein the squamous carcinoma is in the lung.

41. The method of claim 38 , wherein the squamous carcinoma is in the urinary bladder.

42. The method of claim 38 , wherein the adenocarcinoma is in the prostate, small intestine, endometrium, cervical canal, large intestine, lung, panucas, gullet, intestinum rectum, uterus, stomach, mammary gland, or ovary.

43. The method of claim 36 , wherein the anti-PD-L1 antibody is a human antibody or a humanized antibody.

44. The method of claim 1 , wherein the tumor is in the urinary bladder.

45. The method of claim 19 , wherein the tumor is in the urinary bladder.

46. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1, IgG3, or IgG4 isotype.

47. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1 isotype.

48. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1, IgG3, or IgG4 isotype.

49. The method of claim 19 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1 isotype.

50. The method of claim 36 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1, IgG3, or IgG4 isotype.

51. The method of claim 36 , wherein the anti-PD-L1 monoclonal antibody comprises a human heavy chain constant region of an IgG1 isotype.

52. A method of treating a tumor in a human patient in need thereof comprising adminis

Assignees

• Ono Pharmaceutical Co

Inventors

• Honjo Tasuku
• Minato Nagahiro
• Iwai Yoshiko
• Shibayama Shiro

Classifications

• A61P31/10

  Antimycotics · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P31/14

  for RNA viruses · CPC title